The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
复制标题
缺氧成像剂CUII（ATSM）具有神经保护作用，并改善了帕金森氏病多种动物模型的运动和认知功能。
DOI：
10.1084/jem.20112285
复制
发表时间：
2012-04-09
期刊：
影响因子：
--
通讯作者：
Barnham KJ
中科院分区：
文献类型：
--
作者：
Hung LW;Villemagne VL;Cheng L;Sherratt NA;Ayton S;White AR;Crouch PJ;Lim S;Leong SL;Wilkins S;George J;Roberts BR;Pham CL;Liu X;Chiu FC;Shackleford DM;Powell AK;Masters CL;Bush AI;O'Keefe G;Culvenor JG;Cappai R;Cherny RA;Donnelly PS;Hill AF;Finkelstein DI;Barnham KJ
PET显像剂CUII(ATSM)可改善帕金森病患者的运动和认知功能。帕金森病(PD)是一种进行性慢性疾病，以运动障碍、僵硬、不稳定和震颤为特征。该病的定义是路易小体的存在，主要由聚集的α-突触核蛋白组成，并伴有单胺能神经元的丢失。目前的治疗策略只给出了运动障碍的症状缓解，而没有解决潜在的神经变性。因此，我们确定CUII(ATSM)是一种潜在的帕金森病治疗方法。四种不同帕金森病动物模型给药后，运动和认知功能得到改善，黑质细胞丢失得到挽救，多巴胺代谢得到改善。在体外，该化合物能够抑制过氧亚硝酸盐驱动的毒性作用，包括硝化α-突触核蛋白寡聚体的形成。我们的结果表明，CUII(ATSM)在逆转帕金森氏症动物模型中是有效的，并具有成功治疗帕金森病的潜力。
The PET imaging agent CuII(atsm) improves motor and cognitive function in Parkinson’s disease. Parkinson’s disease (PD) is a progressive, chronic disease characterized by dyskinesia, rigidity, instability, and tremors. The disease is defined by the presence of Lewy bodies, which primarily consist of aggregated α-synuclein protein, and is accompanied by the loss of monoaminergic neurons. Current therapeutic strategies only give symptomatic relief of motor impairment and do not address the underlying neurodegeneration. Hence, we have identified CuII(atsm) as a potential therapeutic for PD. Drug administration to four different animal models of PD resulted in improved motor and cognition function, rescued nigral cell loss, and improved dopamine metabolism. In vitro, this compound is able to inhibit the effects of peroxynitrite-driven toxicity, including the formation of nitrated α-synuclein oligomers. Our results show that CuII(atsm) is effective in reversing parkinsonian defects in animal models and has the potential to be a successful treatment of PD.
登录
查看更多内容
影响因子：
16.2
作者：
Giasson, BI;Duda, JE;Lee, VMY
通讯作者：
Lee, VMY
DOI：
10.1073/pnas.1116227108
发表时间：
2012-01-03
影响因子：
11.1
作者：
Donnelly, Paul S.;Liddell, Jeffrey R.;Crouch, Peter J.
通讯作者：
Crouch, Peter J.
影响因子：
6
作者：
Culvenor, JG;McLean, CA;Li, QX
通讯作者：
Li, QX
影响因子：
2.7
作者：
ENNACEUR, A;DELACOUR, J
通讯作者：
DELACOUR, J
影响因子：
6
作者：
Duda, JE;Giasson, BI;Trojanowski, JQ
通讯作者：
Trojanowski, JQ